Drug Profile
Research programme: 3 phosphoinositide dependent protein kinase 1 inhibitors - Vernalis
Latest Information Update: 09 Apr 2021
Price :
$50
*
At a glance
- Originator Vernalis
- Class
- Mechanism of Action 3-phosphoinositide-dependent protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in United Kingdom
- 10 Apr 2007 Preclinical trials in Cancer in United Kingdom (unspecified route)